NCT03028909 is a Phase 2 clinical trial of Oseltamivir in Influenza - Type A Strains, sponsored by MedImmune LLC.

Who is sponsoring NCT03028909?

NCT03028909 is sponsored by MedImmune LLC.

What drugs are being tested in NCT03028909?

Interventions in NCT03028909: Oseltamivir, MEDI8852, Placebo.

What condition does NCT03028909 study?

NCT03028909 studies Influenza - Type A Strains.

Is NCT03028909 still recruiting?

NCT03028909 is currently withdrawn. Last updated 14 March 2019.

Last reviewed 2019-03-14 · How we verify

NCT03028909

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.

Withdrawn Phase 2 Last updated 14 March 2019

What this trial tests

Phase 2 trial testing Oseltamivir in Influenza - Type A Strains. Withdrawn.

Timeline

24 July 2017

Primary endpoint
26 July 2019

26 July 2019

Quick facts

Lead sponsor	MedImmune LLC
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Start date	24 July 2017
Primary completion	26 July 2019
Estimated completion	26 July 2019

Drugs / interventions tested

Oseltamivir — full drug profile →
MEDI8852 — full drug profile →
Placebo

Conditions studied

Influenza - Type A Strains — all drugs for Influenza - Type A Strains →

Sponsor

MedImmune LLC — full company profile →

Who can join

Adults 18 to 99, any sex, with Influenza - Type A Strains. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purposes of this study are to determine if MEDI8852 administered with standard of care (oseltamivir) will reduce the time to normalization of respiratory function for adults who are hospitalized with influenza caused by Type A strains and to determine if MEDI8852 has an acceptable safety profile in adults who are hospitalized with influenza caused by Type A strains.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Overview of Current Therapeutics and Novel Candidates Against Influenza, Respiratory Syncytial Virus, and Middle East Respiratory Syndrome Coronavirus Infections.
Behzadi MA, Leyva-Grado VH. · · 2019 · cited 78× · PMID 31275265 · DOI 10.3389/fmicb.2019.01327
Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study.
Hershberger E, Sloan S, Narayan K, Hay CA, et al · · 2019 · cited 68× · PMID 30638863 · DOI 10.1016/j.ebiom.2018.12.051
Promising approaches for the treatment and prevention of viral respiratory illnesses.
Papadopoulos NG, Megremis S, Kitsioulis NA, Vangelatou O, et al · · 2017 · cited 40× · PMID 28739285 · DOI 10.1016/j.jaci.2017.07.001
How Broadly Neutralising Antibodies Are Redefining Immunity to Influenza.
Steventon R, Stolle L, Thompson CP. · · 2025 · cited 5× · PMID 39846612 · DOI 10.3390/antib14010004
Monoclonal antibodies against influenza viruses: a clinical trials review.
Mota KG, Moro AM. · · 2025 · PMID 41142796 · DOI 10.3389/fimmu.2025.1669073

Verify or expand the search:

Other trials of Oseltamivir

Trials testing the same drug.

NCT07496736 — Post-exposure Influenza Prophylaxis in a Hospital Setting · Phase 3 · active not recruiting
NCT07236814 — Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting · Phase 3 · recruiting
NCT07229807 — Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A · Phase 3 · active not recruiting
NCT07357051 — Phase III Clinical Study Evaluating the Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Pa · Phase 3 · recruiting
NCT07113392 — A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension · Phase 3 · not yet recruiting

Other MedImmune LLC trials

Trials by the same sponsor.

NCT04145193 — Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC · Phase 2 · withdrawn
NCT04522323 — A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma · Phase 1 · active not recruiting
NCT03903718 — Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza · Phase 2 · withdrawn
NCT04261075 — IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. · Phase 1 · completed
NCT03889275 — A Study of MEDI5395 in Combination With Durvalumab in Participants With Select Advanced Solid Tumors · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03028909 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedImmune LLC
Last refreshed: 14 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03028909.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing